Dr. Antonio Fojo, MD, PhD
Claim this profileJames J. Peters VA Medical Center, Bronx, NY
Area of expertise
Prostate Cancer
Antonio Fojo, MD, PhD has run 3 trials for Prostate Cancer. Some of their research focus areas include:
Fanconi Anemia
Antonio Fojo, MD, PhD has run 1 trial for Fanconi Anemia. Some of their research focus areas include:
Affiliated Hospitals
James J. Peters VA Medical Center, Bronx, NY
Bronx VA Hospital
Clinical Trials Antonio Fojo, MD, PhD is currently running
Pembrolizumab
for Prostate Cancer
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting
2 awards
Phase 2
3 criteria
Carboplatin vs Olaparib
for Prostate Cancer
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.
Recruiting
1 award
Phase 2
More about Antonio Fojo, MD, PhD
Clinical Trial Related
5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Antonio Fojo, MD, PhD has experience with
- Carboplatin
- Olaparib
- Pembrolizumab
- Docetaxel
- Radium-223
Breakdown of trials Antonio Fojo, MD, PhD has run
Prostate Cancer
Fanconi Anemia
Hereditary Sensory Neuropathy
Breast and ovarian cancer syndrome
RAD51 Gene Mutation
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Antonio Fojo, MD, PhD specialize in?
Antonio Fojo, MD, PhD focuses on Prostate Cancer and Fanconi Anemia. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are MLH1 positive.
Is Antonio Fojo, MD, PhD currently recruiting for clinical trials?
Yes, Antonio Fojo, MD, PhD is currently recruiting for 2 clinical trials in Bronx New York. If you're interested in participating, you should apply.
Are there any treatments that Antonio Fojo, MD, PhD has studied deeply?
Yes, Antonio Fojo, MD, PhD has studied treatments such as Carboplatin, Olaparib, Pembrolizumab.
What is the best way to schedule an appointment with Antonio Fojo, MD, PhD?
Apply for one of the trials that Antonio Fojo, MD, PhD is conducting.
What is the office address of Antonio Fojo, MD, PhD?
The office of Antonio Fojo, MD, PhD is located at: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York 10468-3904 United States. This is the address for their practice at the James J. Peters VA Medical Center, Bronx, NY.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.